Absci, a clinical-stage biotechnology company focused on generative AI-driven therapeutics, has announced a strategic collaboration with Oracle Cloud Infrastructure (OCI) and AMD to enhance its AI Drug Creation Platform. The partnership aims to accelerate the design and development of novel biologics through advanced computational infrastructure and next-generation hardware.
Enhanced AI Infrastructure for Drug Discovery
The collaboration centers on Absci's generative AI Drug Creation Platform, which now leverages OCI's AI infrastructure as its technical foundation for developing AI models and scaling workflows. The platform has demonstrated significant improvements in large-scale molecular dynamics simulations and end-to-end antibody design processes.
"Our mission is to push the boundaries of how we design new therapeutics," said Sean McClain, Founder and CEO of Absci. "With OCI and AMD, we are pairing our cutting-edge AI models with best-in-class infrastructure. This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI-powered drug-discovery workflows."
Technical Performance Improvements
The partnership has enabled substantial technical enhancements to Absci's drug discovery capabilities. OCI's bare metal instances, powered by 5th Generation AMD EPYC processors and ultrafast RDMA cluster networking, provide the low-latency networking and throughput required for large-scale model training and high-resolution molecular dynamics simulations that refine antibody-antigen interactions.
With direct, bare-metal access to AMD GPUs in a single, flat-network supercluster, Absci has eliminated hypervisor overhead and reduced inter-GPU latency to as little as 2.5 microseconds. The system delivers terabytes-per-second throughput for checkpointing and data streaming, significantly enhancing computational efficiency.
Next-Generation GPU Integration
Absci is expanding its collaboration with AMD to incorporate the company's next-generation Instinct MI355X GPUs, designed to further boost the performance and scalability of the AI Drug Creation Platform. This integration represents a significant step forward in computational drug discovery capabilities.
"Absci's generative AI-driven drug discovery is the kind of breakthrough workflow OCI was built for," said Dan Spellman, vice president, AI and OCI, Healthcare & Life Sciences at Oracle. "By combining bare metal GPUs, OCI Compute E6 instances, ultrafast RDMA networking, and high-performance storage, we're providing the predictable performance and close engineering collaboration Absci needs to push the boundaries of biologics design."
Integrated Drug Creation Platform
Absci's Integrated Drug Creation platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. The platform operates through a continuous feedback loop between advanced AI algorithms and wet lab validation, with each cycle refining data and strengthening models to facilitate rapid innovation and enhance therapeutic design precision.
"Absci is demonstrating how AI can transform the pace of drug discovery, and we're proud to support that mission," said Ram Peddibhotla, corporate vice president, Data Center GPU Cloud Business at AMD. "By combining OCI with AMD EPYC CPUs, AMD Instinct GPUs and our open ROCm software platform, this collaboration provides the performance and scalability needed to advance complex biologics design and support more efficient discovery workflows."
The collaboration represents a significant advancement in computational drug discovery, positioning Absci to accelerate the development of novel therapeutics through enhanced AI-driven design capabilities and infrastructure optimization.
